header logo image


Page 6«..5678..20..»

Archive for the ‘Fat Stem Cells’ Category

The rise of ‘rich woman face’: how to halt the ageing process (for a certain price) – Telegraph.co.uk

Monday, April 6th, 2020

'Let me tell you about the very rich,' wrote F Scott Fitzgerald. 'They are different from you and me.' Above all, in the lengths they will go to acquire, and preserve, perfect skin.

Sheikha Moza bint Nasser, the consort of the former Emir of Qatar, may well be the richest person I've ever met. She certainly has skin like no one else on the planet. She's 61 but looks about 40, with a face that seems to have no visible pores, perhaps because it's sculpted out of alabaster.

Admittedly, she is carefully made-up on a regular basis, so she would have been unlikely to want to attend a recent dinner party of Gwyneth Paltrow's in Beverly Hills, at which guests were banned from wearing any cosmetics at all. Kate Hudson and Demi Moore were among those who gamely took the challenge, the idea of which was to allow the assembled LA A-listers to show off their natural glow.

But they don't, of course, rely wholly on nature for their radiance. Moore's evening beauty routine (pared back to the minimum because, she says, "I like to keep it simple") includes eight separate products, with a total cost of 743.50, from a cleansing elixir to a 355 replenishing facial oil and a rose-quartz facial massager in the shape of a butterfly.

No wonder that, far from being petrified at the thought of the make-up-free dinner, she felt 'full of joy', according to her Instagram posts. Her face wasn't coated in foundation, but it was insulated by a thick layer of cash.

With skincare that promises actually to reverse the visible signs of ageing, beauty brands feel entitled to charge impressive sums. La Prairie has one serum, its Platinum Night Elixir, that sells for over 1,000 for 20ml. It costs about 10 more per gram than solid gold. Imagine if your cat knocked that one off the dressing table.

On the other hand, the scientist who developed it says the peptides and amino acids contained in a single daily drop will leave your skin visibly younger-looking and fresher in two weeks. Users say it feels like wrapping your face in cashmere.

La Prairie Platinum Rare Cellular Night Elixir 20ml, 1,018, Harvey Nichols

I rely on Dr Phillip Levy, a Swiss dermatologist and wound-healing specialist based in Geneva, whose moisturisers and serums are proven to revitalise dermal stem cells to kick-start your skin's own production of collagen. Another doctor - German-born Michael Prager, who operates from a clinic in Wimpole Street - emphasises the rejuvenating effects of combating pollution with an antioxidant cream that fights off free radicals.

Neither of these medical-grade ranges comes cheap, but though Dr Prager's day oil contains pure gold, at 225 for 30ml (drmichaelprager.com), it's not actually as expensive as buying the precious metal itself.

If you're going down the Sheikha Moza route to moneyed perfection with a lavish use of make-up, Gucci Westman is a name to conjure with. This make-up artist, who has worked with Natalie Portman and Nicole Kidman, has her own range, Westman Atelier.

Lip suede in Les Rouges, 75, Westman Atelier (net-a-porter.com)

Yes, the colours are lush but, even better, the brand is 'clean' - beauty-speak for vegan, against animal-testing, paraben-free and so on. Plus, the products moisturise, plump up collagen and soothe as you apply them. Even the mascara conditions your lashes. So what if it costs 58?

Equally impressive is Shiseido's luxury line, Cl de Peau, which does a foundation that's 250 for 27ml, in 13 shades. Again, it's a beauty treatment with SPF and moisturiser as much as a make-up product, and it's what I'll put on if I want anyone to tell me I look glowing.

But, of course, more precious than any cream or blush stick is a little personal attention. Dr Costas Papageorgiou operates out of Harrods and has fairly expensive-looking skin himself. He makes use of a battery of lasers, Botox, fillers and ultrasound, but the key to his success is the consultation that starts off the process.

The Foundation,250, Cl de Peau Beaut (harrods.com)

Seeing your own face in unforgiving 3D on a computer may be a shock, but it certainly helps pinpoint the areas you'd like him to focus on. He's very hot on correcting facial symmetry, which starts out pretty good in babies, but with time and use, the muscles on the face become less symmetrical as bits start to droop or wrinkle. Generally, the more lopsided you are, the more antique you look, and he can address that with filler, Botox and even thread lifts.

But I'm not one for the injectables. It's his Hybrid Energy Lift - a combination of ultrasound, infrared, light and laser - that I really rate (from 6,000 for 120 minutes, facialplasticslondon.com). It, too, stimulates collagen production, but it also gets rid of visible veins and redness, and even reduces big pores. I have had to change the tone of my foundation for a paler one since he did for my (mild) rosacea.

Radical3 Reboot Pro Peel, 89, Dr Levy (editorslist.co.uk)

The key, says Dr Papageorgiou, is to delay and reverse the "ageing cascade". This slow car crash of fine lines around the eyes, sun damage and heavy jowls is all thanks, he says, to "fat atrophy and bone resorption".

But subtlety is all - "A great result is one that shows no signs of intervention"- and nothing, he warns, can really be achieved unless you have a healthy diet, exercise and take vitamins.

Debbie Thomas, at her D.Thomas clinic in London, has a similarly personalised approach. You don't book in for a single treatment, you book for an hour of her expert time, and she'll use a cocktail of lasers, micro-needling and products depending on what you need (475 for a DNA Laser Complete 2 session, dthomas.com).

"I'm afraid,"she says, "traditional facials are not going to transform your skin for more than a few days. You need to upgrade to more advanced treatments if you want long-term results. And those will be more costly."And who can say it's not worth the money?

Sign up for theTelegraphLuxury newsletterfor your weekly dose of exquisite taste and expert opinion.

See more here:
The rise of 'rich woman face': how to halt the ageing process (for a certain price) - Telegraph.co.uk

Read More...

Scientists Have ‘Reset’ The Cellular Age Of Cells Taken From A 114-Year-Old Woman – IFLScience

Friday, March 27th, 2020

For the first time, scientists have reprogrammed cells from a 114-year-old woman into induced pluripotent stem cells (iPS cells), a move which they describe as a significant step toward understanding"the underlying mechanisms of extreme longevity and disease resistance."

iPS cells are adult cells that have been genetically reprogrammed into an embryonic stem cell-like state and are able to give rise to any of the specialized cell types of the body, whether its neurons, blood cells, or heart cells.

Until this new project, researchers werent even certain whether they could create viable iPS cellsfrom someone so elderly, let alone a supercentenarian. Now they have shown it's possible to effectively make these aged cells resemble young pluripotent cells, the researchers believe they might have made a step towards the reversal of cellular aging.

"We set out to answer a big question: Can you reprogram cells this old?" Evan Snyder, stem cell researcher at Sanford Burnham Prebys Medical Discovery Institute in California, said in a statement.

"Now we have shown it can be done, and we have a valuable tool for finding the genes and other factors that slow down the aging process."

Reporting in the journal Biochemical and Biophysical Research Communications, researchers harnessed iPS cells from the blood cells of a 114-year-old woman, a healthy 43-year-old person, and an 8-year-old child with a rare genetic condition characterized by the rapid aging in childhood. These iPS cells were then turned into mesenchymal stem cells, cells that help maintain and repair the body's structural tissues differentiating into bone, cartilage, muscle, or fat cells.

Remarkably, the cells produced from the supercentenarian transformed just as easily as the others. They also noted the supercentenarian-derived stem cells appeared to have reset their telomeres.

Telomeresarethe protective caps on the end of a chromosome. Since they shorten each time a cell copies itself, they also get shorter as we age and eventually stop functioning properly. Thispersistent shortening allows researchers to use telomeres as a kind of aging clock in every cell.Interestingly, the stem cells from the supercentenarian showed no indication of this aging. They had effectively reset the clock on the cells from114 years to zero.

To dive deeper into this discovery, the researchers hope to compare body cells derived from the healthy iPSCs and supercentenarian iPSCs. The researchers could also start to use the supercentenarian cells to understand why certain people have such long lives compared to others.

Why do supercentenarians age so slowly? We are now set to answer that question in a way no one has been able to before, said Snyder.

Read more from the original source:
Scientists Have 'Reset' The Cellular Age Of Cells Taken From A 114-Year-Old Woman - IFLScience

Read More...

This Is Why Soap Is So Effective at Stopping Spread of Coronavirus – Newsweek

Saturday, March 14th, 2020

With fear and misinformation spreading alongside the new coronavirus, a scientist has explained why a humble bar of soap is one of the most important weapons in our arsenal against the bug which causes COVID-19.

Soap wipes out viruses including SARS-CoV-2the pathogen which causes the disease COVID-19 not to be confused with the SARS virusbecause it is able to dissolve its fat membrane, explained Palli Thordarson, a chemistry professor at the University of New South Wales.

In a Twitter thread, Thordarson said this causes the virus to fall apart "like a house of cards" and become inactive (but not die as they aren't technically alive). Water alone isn't enough, according to Thordarson, because it "'only' competes with the strong 'glue-like' interactions between the skin and virus via hydrogen bonds. They virus is quite sticky and may not budge."

"Soapy water is totally different," said Thordarson. "Soap contains fat-like substances knowns as amphiphiles, some structurally very similar to the lipids in the virus membrane. The soap molecules "compete" with the lipids in the virus membrane."

And as our hands are "quite rough and wrinkly," we need to rub and soak them to make sure the soap reaches every part of the skin, he said.

Thordarson went on to address why soap works better to deactivate viruses than other products. "Disinfectants, or liquids, wipes, gels and creams containing alcohol (and soap) have a similar effects but are not really quite as good as normal soap. Apart from the alcohol and soap, the 'antibacterial agents' in these products don't affect the virus structure much at all."

"Consequently, many antibacterial products are basically just an expensive version of soap in terms of how they act on viruses. Soap is the best but alcohol wipes are good when soap is not practical or handy (e.g. office receptions)," he said.

Donald Schaffner, distinguished professor at Rutgers University and an expert in topics including handwashing, told Newsweek soaps also work to remove viruses from the hands as they wash them down the drain, while hand sanitizers inactivate virus already on the hands. "For an added 'one-two' punch you can use both," he said.

Contrary to some recommendations that hot water must be used when handwashing, Schaffner said the level of heat doesn't matter and people should simply use a comfortable temperature.

"People should practice washing all the areas of their hands, and perhaps give special attention to places where microbes may get trapped in dirt such as under the fingernails," he said.

Schaffner added: "Alcohol-based hand sanitizers are very effective against this virus. There are some viruses like norovirus, where hand sanitizers don't work as well." That's not the case with SARS-CoV-2 because of its structure, he said.

"Of course it doesn't help that many store shelves are sold out, but I would recommend getting a bottle to have on hand the next time it's available," said Schaffner.

The advice is in line with that given by the World Health Organization, which last month urged the public to "never underestimate the power of the humble bar of soap!"

"Washing your hands regularlyeither with alcohol-based rub or ordinary soap and wateris one of the most effective ways to protect yourself and others from #COVID19 and many other diseases."

For more WHO advice of preventing the spread of COVID-19, scroll to the bottom of the piece.

The U.S. Centers for Disease Control and Prevention advises people to sing the Happy Birthday song twice, which lasts about 20 seconds, while washing their hands to ensure they are doing so for long enough to rid their hands of germs.

After you've washed your hands, don't forget to moisturise, Dr. Sara Hogan, a dermatologist at UCLA Medical Center, told Slate. That's because the practice can disturb the outer layer of skin which is made up of dead cells and protects our skin from dirt and microbes, and locks in moisture.

Dr. Evan Rieder, a dermatologist at NYU Langone told the website "really greasy" moisturizers and emollients are best, followed by creams and lotions which contain more water and are therefore less hydrating.

All this can help to stem the spread of the COVID-19, which has killed over 3,800 people in 111,000 cases worldwide, with more than 62,300 people recovered, according to a tracker run by Johns Hopkins University.

Most deaths have occurred in Hubei, China, where the outbreak started in the province's capital of Wuhan in December 2019. As shown in the map below by Statista the virus has reached every continent except Antarctica.

Hygiene advice

Medical advice

Mask usage

This article has been updated with comment from Donald Schaffner.

Originally posted here:
This Is Why Soap Is So Effective at Stopping Spread of Coronavirus - Newsweek

Read More...

2018 Today Show Book Recommendations: picks this week – Today.com

Saturday, March 14th, 2020

We often have guests come on the TODAY show to talk about their newest book. Here's where to buy them.

"The Photo Ark: One Man's Quest to Document the World's Animals," by Joel Sartore, $24, Amazon

"Cook Like a Pro," by Ina Garten, $17, Amazon

"More Beautiful Than Before," by Steve Leder, $12, Amazon

"Shame Nation," by Sue Scheff and Melissa Schorr, $11, Amazon

"Short Cuts to Happiness," by Dr. Tal Ben-Shahar, $13, Amazon

"Salt, Fat, Acid, Heat," by Samin Nosrat, $15, Amazon

"The Secret Ingredient," by Gigi Butler, $18, Amazon

"Everyday Magic for Kids," by Justin Flom $9, Amazon

"Eat What You Love," Danielle Walker, $17, Amazon

"High," by David and Nick Sheff, $12, Amazon

"Tony's Wife," by Adriana Trigiani, $19, Amazon

"You're Not That Great (But Neither is Anyone Else)," by Elan Gale, $14, Amazon

"Godwink Christmas Stories," by SQuire Rushnell and Louise DuArt, $14, Amazon

"Homebody," by Joanna Gaines, $24, Amazon

"The Whole Foods Cookbook," by John Mackey, Alona Pulde and Matthew Lederman, $18, Amazon

"Fantastical Cakes," by Gesine Bullock-Prado, $19, Amazon

"The Power of Love," by Bishop Michael Curry, $16, Amazon

"Martina's Kitchen Mix," by Martina McBride, $19, Amazon

"OtherEarth," by Jason Segel and Kristen Miller, $13, Amazon

"The Southern Living Party Cookbook," by Elizabeth Heiskell, $32, Amazon

"College Admission 101," by Princeton Review and Robert Franek, $9, Amazon

"All About Cake," by Christina Tosi, $22, Amazon

"My Squirrel Days," by Ellie Kemper, $17, Amazon

"Sisters First," by Jenna Bush Hager and Barbara Pierce Bush, $14, Amazon

"Buseyisms," by Gary Busey, $17, Amazon

"Chasing the Gator," by Isaac Toups and Jennifer V. Cole, $22, Amazon

"The Gift That I Can Give," by Kathie Lee Gifford, $13, Amazon

"Cook Like a Pro," by Ina Garten, $21, Amazon

"Trump, the Blue-Collar President," by Anthony Scaramucci, $18, Amazon

"How to Stay Alive," by Bear Grylls, $13, Amazon

"One Heart at a Time," by Delilah, $18, Amazon

"Comfort in an Instant," by Melissa Clark, $15, Amazon

"Where You Go: Life Lessons from my Father," by Charlotte Pence, $17, Amazon

"Mix-and-Match Mama Meal Planner," by Shay Shull, $13, Amazon

"Candace Center Stage," by Candace Cameron Bure, $16, Amazon

"I Love You More Than...," by Taye Diggs, $13, Amazon

"Max Einstein: The Genius Experiment," by James Patterson and Chris Grabenstein, $9, Amazon

"Target: Alex Cross," by James Patterson, $19, Amazon

"Elbow Grease," by John Cena, $13, Amazon

"Fame: The Hijacking of Reality," by Justine Bateman, $17, Amazon

"Dear Evan Hansen: The Novel," $13, Amazon

Stuff We Love

Get a daily roundup of items that will make your life easier, healthier and more stylish.

"Presidents of War," by Michael Beschloss, $17, Amazon

"Joy's Simple Food Remedies," by Joy Bauer, $14, Amazon

"Builder Brothers: Big Plans," by Drew and Jonathan Scott, $16, Amazon

Super Satya Saves the Day," by Raakhee Mirchandani, $20, Amazon

"Struck," by Douglas Segal, $13, Amazon

"Next Level Thinking," by Joel Osteen, $13, Amazon

"Pull Up a Chair," by Tiffani Thiessen, $17, Amazon

"I Love California: Live, Eat, and Entertain the West Coast Way," by Nathan Turner, $27, Amazon

"American Like Me," by America Ferrera, $14, Amazon

"Know Your Value," by Mika Brzezinski, $14, Amazon

"This is the Day," by Tim Tebow, $15, Amazon

"Pop Stars, Pageants & Presidents: How an Email Trumped My Life," by Rob Goldstone, $25, Amazon

"The Magic Misfits: The Second Story," by Neil Patrick Harris, $12, Amazon

"To the Moon and Back: A Childhood Under the Influence," by Lisa Kohn, $16, Amazon

"Princesses Save the World," by Savannah Guthrie & Allison Oppenheim, $12, Amazon

"Dear America," by Jose Antonio Vargas, $17, Amazon

"Too Big to Fail," by Andrew Ross Sorkin, $15, Amazon

"Fear," by Bob Woodward, $15, Amazon

"Betty Ford," by Lisa McCubin, $15, Amazon

"Perfectly Clear," My Michelle LeClair, $14, Amazon

"Live Long and...," by William Shatner, $18, Amazon

"Small Fry," by Lisa Brennan-Jobs, $17, Amazon

"Turning Pages" by Sonia Sotomayor, $18, Amazon

"The Beloved World of Sonia Sotomayor," by Sonia Sotomayor, $12, Amazon

"Me, Myselfie & I," by Jamie Lee Curtis and Laura Cornell, $18, Amazon

"It's Momplicated," by Debbie Alsdorf and Joan Edwards Kay, $13, Amazon

"Pressure Cooker," by Martha Stewart, $20, Amazon

"Real Life Dinners," by Rachel Hollis, $13, Amazon

"Cuddly Critters for Little Geniuses," by James and Sue Patterson, $13, Amazon

"What Can You Do with a Toolbox?" by John Colaneri, Anthony Carrino and Maple Lam, $11, Amazon

"Princesses Save the World" by Savannah Guthrie and Allison Oppenheim, $13, Amazon

"Princesses Save the World" by Savannah Guthrie and Allison Oppenheim, $13, Amazon

This one is available for pre-order now and officially comes out on September, 18.

"The Freds at Barneys New York Cookbook" by Mark Strausman and Susan Littlefield, $17, Amazon

"The Freds at Barneys New York Cookbook" by Mark Strausman and Susan Littlefield, $17, Amazon

"Unfiltered: How to Be as Happy as You Look on Social Media" by Jessica Abo and Kelly Rutherford, $21, Amazon

"Unfiltered: How to Be as Happy as You Look on Social Media" by Jessica Abo and Kelly Rutherford, $21, Amazon

"Unhinged: An Insider's Account of the Trump Whitehouse" by Omarosa Manigault Newman, $15, Amazon

"Unhinged: An Insider's Account of the Trump Whitehouse" by Omarosa Manigault Newman, $15, Amazon

"Comfort in an Instant: 75 Comfort Food Recipes for Your Pressure Cooker, Multicooker, and Instant Pot" by Melissa Clark, $13, Amazon

"Comfort in an Instant: 75 Comfort Food Recipes for Your Pressure Cooker, Multicooker, and Instant Pot" by Melissa Clark, $13, Amazon

"Spying on Whales" by Nick Pyenson, $14, Amazon

"Spying on Whales" by Nick Pyenson, $14, Amazon

"Ruthless Tide" by Al Roker, $15, Amazon

"Ruthless Tide" by Al Roker, $15, Amazon

"Fail Until You Don't: Fight Grind Repeat" by Bobby Bones, $13, Amazon

"Fail Until You Don't: Fight Grind Repeat" by Bobby Bones, $13, Amazon

"First, We Make the Beast Beautiful: A New Journey Through Anxiety" by Sarah Wilson, $13, Amazon

"First, We Make the Beast Beautiful: A New Journey Through Anxiety" by Sarah Wilson, $13, Amazon

"Born Trump: Inside America's First Family" by Emily Jane Fox, $15, Amazon

"Born Trump: Inside America's First Family" by Emily Jane Fox, $15, Amazon

"A Place for Us" by Fatima Farheen Mirza, $14, Amazon

"A Place for Us" by Fatima Farheen Mirza, $14, Amazon

"Homebody: A Guide to Creating Spaces You Never Want to Leave" by Joanna Gaines, $20, Amazon

"Homebody: A Guide to Creating Spaces You Never Want to Leave" by Joanna Gaines, $20, Amazon

"Broken Bananah: Life, Love and Sex ... Without a Penis" by Ross Asdourian, $16, Amazon

View original post here:
2018 Today Show Book Recommendations: picks this week - Today.com

Read More...

Will Beyond Meat and Impossible Foods Survive Lab Meats Challenge? – Motley Fool

Friday, March 6th, 2020

Some analysts predict the emerging science of cultured meat -- aka lab meat or synthetic meat -- could threaten the market share of "plant-based meat" producers like Beyond Meat (NASDAQ:BYND), Impossible Foods, and others in the near future. Growing meat separate from an animal might possibly solve the ethical, environmental, and culinary issues of meat and meat substitutes in one fell swoop. But while Fools investing in food stocks centered on plant-based meat may wonder whether lab meat threatens their portfolio's value, other evidence suggests it might be a proverbial "nothingburger" after all.

People first thought about cultured meat in the 1930s, and scientists grew the first meat outside an animal in the early 1970s. However, methods are just now getting sophisticated enough to produce affordable, high-quality lab meat.

To grow cultured meat, scientists place animal cells (muscle stem cells, fat cells, and collagen) in a nutritional medium inside a bioreactor where they can multiply. Artificial circulation carries nutrients and oxygen to the multiplying cells. The overall process is called "cellular agriculture."

Producing meat while avoiding the death of living animals is cellular agriculture's primary attraction for many people. Scientists also believe it's possible to make the meat healthier while growing it, raising protein content, lowering saturated fat levels (possibly to zero), and enhancing its vitamin content. Proponents also cite cultured meat's environmental benefits, since it doesn't require land deforestation to make space for grazing land, involves far lower water inputs, and might release fewer greenhouse gases.

Image source: Getty Images

Based on these factors, some analysts expect explosive growth in lab meat once it's launched in the next few years. A.T. Kearney projects a compound annual growth rate (CAGR) of 41% for cultured meat between 2025 and 2040, capturing 35% of the global meat market by 2040. During the same period, they predict 9% CAGR for plant-based meats. Additionally, plant-based meat growth is front-loaded in their model, slowing rapidly and gaining less than 0.5% annually closer to 2040, for a total 25% market share. Conventional meat, in their projection, will experience negative growth, shrinking at 3% annually and dwindling to 40% of the market.

Cultured meat is still too expensive for mass appeal or budgets, but its price trajectory over the past few years shows an exponential drop as technology rapidly improves. In 2013, Professor Mark Post produced the first fully cultured hamburger for slightly more than $300,000, or $1.2 million per pound. By 2017, four years later, Memphis Meats grew chicken meat via cellular agriculture for $9,000 a pound, slashed to $1,000 per pound the following year. One year after that, in 2019, Aleph Farms managed to create lab beef for $100 per pound.

Commercial production of cultured meat appears from these figures to be on the cusp of feasibility. The first lab meats may feature on restaurant menus or perhaps specialized grocery shelves in 2020 or 2021. Simply producing the meat at an affordable price doesn't ensure its dominance over standard meat or plant-based meats, though. Lab meat still needs to prove how it stacks up against these established alternatives.

Plant-based meats and cultured meat will probably go head to head in three main areas to determine which will win the biggest market share: ethics, environmental impact, and flavor. While lab meat has strengths in each of these areas, plant-based meats have also come a long way from the limp, tasteless, poorly textured soy patties of yore. Some of lab meat's advantages might not be as large as certain analysts paint them.

When it comes to ethical considerations, it's very difficult to measure potential changes in consumer preference, especially among vegans and vegetarians. Nevertheless, plant-based meats appear to have an unassailable advantage in this area. Since they are made of plant ingredients, they are fully vegetarian and vegan. Cultured meat, on the other hand, still carries potential ethical baggage from the viewpoint of vegans.

Nevertheless, lab meat could potentially capture some of the vegan market among those less concerned with deeper ethical questions, and who simply object to killing animals. Similarly, some people who currently eat meat might switch to lab meat, preferring a "killing-free" alternative even if they'll eat standard meat in the absence of cultured substitutes. Lab meat could also potentially make market inroads in so-called "mixed" households where meat-eaters and vegans live together, helping make the "carnists'" dietary preferences less objectionable to the vegans.

According to Piplsay research, 15% of Americans have tried plant-based meat substitutes because they wanted to go vegan or vegetarian, but wanted a way to sate their meat cravings. Though nowhere near a precise analog, this statistic might give a vague clue about the minimum percent of vegans who might be expected to try lab meat.

Cultured meat advocates cite the eco-friendly nature of their product, which uses much less water and land than livestock farms while moderately reducing energy use. However, according to research carried out jointly by Impossible Foods and Quantis, plant-based meats offer practically identical environmental benefits -- though that study did not measure energy use:

Assuming this data is accurate, lab meat -- while certainly far "greener" than conventional meat -- holds no environmental edge over plant-based meats.

Taste, texture, "mouthfeel," practical use in meat-based recipes, and other measures related to the culinary appeal of meat substitutes are the third area where lab meat needs to prove itself competitive. Where early soy patties were once disgusting to many people, with a flavor quite unlike meat, unpleasant texture, and failure to match the appetizing qualities of actual meat, today's plant-based meats are built to emulate the experience of eating meat as closely as possible.

Beyond Meat, Impossible Foods, and other makers are pouring dollars into plant-based meat research and innovation, making their products as close to meat as possible. Traits engineered into the plant-based meats include correct firmness, juiciness, darkening from pink to brown as they cook, and even "bleeding" for those who want a rare burger or steak.

According to taste testers from Food & Wine, at least, the wizards in Beyond's and Impossible's labs have largely succeeded, very closely imitating the taste of actual meat, creating suitably crumbly burgers that taste right with condiments and match up to the correct texture and juiciness. Other brands are less successful, tasting more like "veggie burgers" than meat.

As far as lab meat is concerned, those who have tried it and reported on the experience say that it tastes rather like chicken or beef found in McDonald's food. While some people might judge that a somewhat dubious recommendation, lab meat will likely hold its own alongside standard burgers and chicken, and the better plant-based meats. We'll need to wait and see whether that's significant enough to make a difference when plant-based alternatives taste much the same.

While commercial cultured meat is clearly coming soon, Beyond Meat and Impossible Foods can probably rest easy as long as they don't get complacent. Their products already closely emulate the experience of eating meat, while avoiding all the ethical issues and matching cellular agriculture one-for-one in terms of eco-friendliness.

Lab meat, once cheap enough for common consumption and improved enough to have culinary appeal, will undoubtedly win over some converts. Some vegans may want to return to the experience of eating "real" meat without the guilt, while some meat-eaters will prefer killing-free meat even if they're not willing to go to extent of eating plant substitutes in order to get it. Mixed households might find it useful for keeping the peace in the kitchen while still giving everyone the dietary items they want.

However, cultured meat's rise to dominance, as predicted by some analysts, seems a somewhat improbable scenario. Plant-based meats got there first, offer the same eating experience, and lack some of cultured meats' lingering downsides. Beyond Meat, Impossible Foods, and other plant-based meat producers will likely enjoy strong long-term viability despite cellular agriculture and, if its upsurge appears strong enough, they may have the cash on hand to simply acquire some of the best new brands and use their existing infrastructure to turn them into an even bigger success.

View post:
Will Beyond Meat and Impossible Foods Survive Lab Meats Challenge? - Motley Fool

Read More...

How industry hopes to take on COVID-19 – Bioprocess Insider – BioProcess Insider

Friday, March 6th, 2020

The biopharma space has stepped up its efforts to both prevent and treat the coronavirus (SARS-CoV-2) that is threatening to bring the world to its knees.

A month is a very long time when it comes to infectious diseases. The first cases and deaths from the novel coronavirus (COVID-19) led to a response to contain the virus, but the difficulties of containment and the nature of international travel means cases and deaths have become global.

The latest statistics place the number of cases at 95,483 and deaths at 3,286 across 84 countries, though by the time you are reading this the number is likely to have skyrocketed.

So as the world tilters on the edge of a pandemic, we take a look at how industry is responding. There is no specific treatment for the virus, nor a vaccine, but a proactive response is seeing the pharma industry throw everything in its arsenal at attempting to stymie this global threat.

First off, vaccines. As the World Health Organization (WHO) states it can take a number of years for a new vaccine to be developed, it has not stopped companies and academia stepping up their R&D efforts.

Both Sanofi and J&J have separately teamed up with the US Department of Health and Human Services (HHS) to expediate vaccine development.

Sanofi Pasteur aims to reverse engineer proteins isolated from the virus to produce DNA sequences, which will then be mass produced using Sanofi Pasteurs baculoviral expression system and formulated into a vaccine that elicits an immune response. Well that is the aim.

Johnson & Johnsons unit Janssen Pharmaceutical, meanwhile, is reviewing products in development for Middle East Respiratory Syndrome (MERS) or Severe Acute Respiratory Syndrome (SARS), to identify promising candidates for the novel coronavirus, and aims to upscale production and manufacturing capacities, leveraging its AdVac and PER.C6 technologies.

Another Big Vaccine company, GlaxoSmithKline, has teamed with Chinese biotech Clover Biopharmaceuticals to help develop a preclinical protein-based vaccine candidate. GSK will provide its pandemic adjuvant system for further evaluation of Clovers S-Trimer, a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate produced using a mammalian cell-culture based expression system.

Inovio Pharmaceuticals has also entered the race, and like GSK has teamed up with a Chinese company. Together with Beijing Advaccine Biotechnology and a grant of up to $9 million from the Coalition for Epidemic Preparedness Innovations (CEPI), Inovio hopes to bring its DNA vaccine candidate INO-4800 rapidly into clinical trials. VGXI a subsidiary of GeneOne Life Science has been selected to manufacture the DNA vaccine from its facilities in The Woodlands, Texas.

Thegenome sequence for 2019-nCoVwas published on January 10, 2020, a VGXI spokesperson recently toldBioprocess Insider. This DNA sequence information is used by Inovio and their collaborators at the Wistar Institute to design a synthetic DNA plasmid for manufacturing at VGXI. No viral particles or proteins are involved in the manufacturing process. When delivered as a vaccine, the DNA plasmid can elicit a protective immune response.

RNA vaccines are also being investigated. Moderna Therapeutics recently shipped the first batch of its investigational messenger RNA vaccine mRNA-1273 to the National Institute of Allergy and Infectious Diseases (NIAID) for use in a Phase I study. The vaccine is designed to train the immune system to recognize cells invaded by the coronavirus.

Moderna also received a grant from CEPI, as has CureVac, which is looking to use its mRNA vaccine platform to expedite a candidate into trials. CureVacs technology and mRNA platform are especially suitable to rapidly provide a response to a viral outbreak situation like this, said CureVac CTO Mariola Fotin-Mleczek. Currently, we are in the process of developing a vaccine that, after successful preclinical tests, could be tested rapidly in humans in a clinical study.

But industry could be pipped to the clinical trial post by academia, with Israels MIGAL Research Institute claiming to be sitting on a human vaccine against COVID-19 as a by-product of a vaccine it has developed against avian coronavirus Infectious Bronchitis Virus (IBV).

From research conducted at MIGAL, it has been found that the poultry coronavirus has high genetic similarity to the human COVID-19, and that it uses the same infection mechanism, a fact that increases the likelihood of achieving an effective human vaccine in a very short period of time, the Institute says.

According to MIGALs Biotechnology group leader Chen Katz, the vaccine is based on a new protein expression vector, which forms and secretes a chimeric soluble protein that delivers the viral antigen into mucosal tissues by self-activated endocytosis a cellular process in which substances are brought into a cell by surrounding the material with cell membrane, forming a vesicle containing the ingested material causing the body to form antibodies against the virus.

Other pharma companies are looking to treat coronavirus, rather than prevent.

Regeneron has teamed with the HHS to use its VelociSuite technologies to identify and validation and develop preclinical candidates and bring them to development, having followed a similar approach to advance its investigational Ebola treatment REGN-EB3.

The tech platform includes the VelocImmune mouse technology, a genetically modified strain in which genes encoding mouse immune system proteins have been replaced by their human equivalents.

The life-saving results seen with our investigational Ebola therapy last year underscore the potential impact of Regenerons rapid response platform for addressing emerging outbreaks, said George Yancopoulos, Regeneron CSO. Our unique suite of technologies expedites and improves the drug discovery and development process at every stage, positioning Regeneron to respond quickly and effectively to new pathogens.

Meanwhile this week, Takeda announced it is looking to a therapy to target COVID-19 based on polyclonal hyperimmune globulin (H-IG). The candidate, TAK-888, aims to concentrate pathogen-specific antibodies from plasma collected from recovered patients. Initially, due to a lack of current donors, the firm will produce the therapy in a segregated area within its manufacturing facility in Georgia.

The Japan-headquartered firm will also review its current pipeline for any other viable candidates to take on COVID-19.

Such an approach has aided Gilead Sciences efforts. The firm has begun two Phase III clinical studies of its antiviral candidate remdesivir, developed (though never approved) to treat Ebola virus. It has also shown promise against other infectious diseases including Marburg, MERS and SARS.

This is an experimental medicine that has only been used in a small number of patients with COVID-19 to date, so Gilead does not have an appropriately robust understanding of the effect of this drug to warrant broad use at this time, Gilead said.

With about 1,000 patients set to be tested with remdesivir, Gilead has turned to a stockpile manufactured in response to Ebola to address present coronavirus needs, and in anticipation of expanded use is manufacturing two formulations of remdesivir, in both liquid and freeze-dried forms, while upping capacity and production internally and externally.

According to San Marinos Bioscience Institute SpA, a regenerative medicine center and stem cell production facility, mesenchymal stem cells could potentially be treatment for the novel coronavirus by improving lung microenvironment, inhibiting immune system overactivation, promoting tissue repair, protecting lung alveoli epithelial cells, preventing pulmonary fibrosis, and improving lung function.

The company, citing the Chinese open repository for scientific researchers chinaXiv.org , says at least 14 trials are taking place in China using stem cells to treat coronavirus patients after positive animal testing showed stem cells might be able to repair the severe organ damage caused by the virus.

The firm even reports that a critically ill 65-year-old Chinese woman infected with SARS-CoV-2, whose conditions significantly improved after the infusion of mesenchymal stem cells.

If mesenchymal stem cells do prove to be the solution to the potential coronavirus crisis, Bioscience Institute alludes to the advantage that they are obtained from fat cells.

That means that everyone can utilize his/her cells, eliminating any contamination or rejection risk, said Giuseppe Mucci, CEO of Bioscience Institute.

But expanding them to the quantity needed for infusion, that corresponds to at least 1 million cells per kg of weight, takes 2 to 3 weeks. That is why it is useful to cryopreserve a personal reserve of mesenchymal stem cells, that would allow to access an early, more successful, treatment.

Follow this link:
How industry hopes to take on COVID-19 - Bioprocess Insider - BioProcess Insider

Read More...

Despite Pro-Life Claims, Stem Cell Therapy Has Very Real Benefits and Should Be Accessible – Patheos

Friday, March 6th, 2020

Stem cell research has been the subject of discussion and heated debate for many years. Much of the social and political drama surrounding stem cells is the result of misunderstanding what stem cells are, where they come from, and what they can do for those with injuries and diseases.

Working from a common set of facts is a great way to dispel controversy, however. Whether we fall into the pro-choice or pro-life camp, it is more than evident that supporting stem cell research, including the development of stem cell therapies, is very much a pro-life position to take.

Stem cells function essentially like raw materials for the body. Depending on instructions from the body (or researchers in laboratories), stem cells can become many other types of cells with specialized functions.

The daughters of stem cells either become new stem cells (self-renewal) or they become more specialized cells for use in specific areas of the body (differentiation). These specialized cells include brain cells, heart muscle cells, bone cells, blood cells and others.

There are several reasons why stem cells are the focus of some of the most important medical science research today:

This last avenue of medical research stem cell therapies is the most consequential as well as the most controversial, depending on your point of view. Understanding stem cell therapy and its divisiveness requires understanding where stem cells come from in medical research and why they have considerable palliative potential.

Stem cells come from one of these three sources:

Embryonic stem cells are the most controversial as well as the most important type of stem cells right now. Thanks to a low-information electorate and gross misinformation from within the government, embryonic stem cells remain mired in needless debate.

Despite the rhetoric, these cells arent harvested from slain newborns. Instead, they are carefully gathered from blastocysts. Blastocysts are three-to-five-day-old embryos comprised of around 150 cells. According to some religious-political arguments, blastocysts are potential human beings, and therefore deserve legal protection.

Embryonic stem cells are the most valuable in medical research because they are fully pluripotent, which means they are versatile enough to become any type of cell the body requires to heal or repair itself.

Adults have limited numbers of stem cells in a variety of bodily tissues, including fat and bone marrow. Unlike pluripotent embryonic stem cells, adult stem cells have more limits on the types of cells they can become.

However, medical researchers keep uncovering evidence that adult stem cells may be more pliable than they originally believed. There is reason to believe cells from adult bone marrow may eventually help patients overcome heart disease and neurological problems. However, adult stem cells are more likely than embryonic stem cells to show abnormalities and environment-induced damage, including cell replication errors and toxins.

The newest efforts in stem cell research involve using genetic manipulation to turn adult stem cells into more versatile embryonic variants. This could help side-step the thorny abortion controversy, but its also not clear at present whether these altered stem cells may bring unforeseen side-effects when used in humans.

More research is required to fully understand the medical potential of perinatal stem cells. However, some scientists believe they may in time become a viable replacement for other types of stem cells. Perinatal stem cells come from amniotic fluid and umbilical cord blood.

Using a standard amniocentesis, doctors can extract umbilical cord mesenchymal stem cells, hematopoietic stem cells, amniotic membrane and fluid stem cells, amniotic epithelial cells and others.

Among other things, stem cell therapy is the next step forward for organ transplants. Instead of waiting on a transplant waiting list, patients may soon be able to have new organs grown from their very own stem cells.

Bone marrow transplants are one of the best-known examples of stem cell therapy. This is where doctors take bone marrow cells and induce them to become heart muscle cells.

Stem cell-based therapies hold significant promise across a wide range of medical conditions and diseases. With the right approach, stem cells show the potential to:

As the FDA notes, there is a lot of hype surrounding stem cell therapy. Much of it is warranted, but some of it deserves caution.

According to the FDA, stem cells have the potential to treat diseases or conditions for which few treatments exist. The FDA has a thorough investigational process for new stem cell-based treatments. This includes Investigational New Drug Applications (IND) and conducting animal testing.

However, the FDA notes that not every medical entity submits an IND when they bring a new stem cell therapy to market. It is vital that patients seek out only FDA-reviewed stem cell therapies and learn all they can about the potential risks, which include reactions at the administration site and even the growth of tumors.

The FDA submitted a paper, Clarifying Stem-Cell Therapys Benefits and Risks, to the New England Journal of Medicine in 2017. Its goal is to help patients fully understand what theyre getting themselves into.

For now, a great deal more research is required before we begin deploying stem cell therapies on a larger scale. The only FDA-approved stem cell therapies on the market today involve treating cancer in bone marrow and blood. Some clinics claim their therapy delivers miracle-like cures for everything from sports injuries to muscular dystrophy, but there just isnt enough evidence yet to take them at face value.

Unfortunately, the religious and political climate makes this evidence difficult to achieve. In some parts of the United States, the hostility toward stem cell researchers and medical practitioners has reached dangerous new levels.

Republicans in Ohio and Georgia want to make it illegal for doctors to perform routine procedures on ectopic pregnancies. This condition is life-threatening for the mother and involves the removal of a nonviable embryo from the fallopian tube.

These laws wouldnt just outlaw ectopic pregnancy surgery in the name of potential human life. It would, in fact, require women to undergo a reimplantation procedure after the ectopic pregnancy is corrected by a physician. If this procedure was actually medically possible, it would be dangerous and unnecessary. Thankfully, it doesnt exist outside the nightmarish imaginations of some of the more extreme Christian lawmakers and Planned Parenthood demonstrators.

Acquiring embryonic stem cells from ectopic pregnancies would seem to be the least controversial way to go about it. Unfortunately, even that small step toward medical progress sees itself hampered by reactionary politics.

No matter how theyre acquired, however, the 150 or so cells in blastocysts are packed with medical potential. Its clear that further exploration down this road will unlock unprecedented scientific progress. It will also, almost certainly, save many times more potential life than even the most outlandish estimates of what the achievement will cost us to achieve. Abortions today are rarer and safer than ever, and the vast majority occur within eight weeks of conception.

The medical community is poised for a revolution here, using these and other nonviable embryos and blastocysts. But realizing that potential requires, among other things, that we collectively make peace with modern medicine and family planning.

See the original post:
Despite Pro-Life Claims, Stem Cell Therapy Has Very Real Benefits and Should Be Accessible - Patheos

Read More...

Prof Ziad Mallat leads Cambridge effort to win 30m to tackle leading cause of heart attacks and strokes – Cambridge Independent

Friday, March 6th, 2020

It is the worlds biggest killer and yet we dont fully understand the leading cause behind it.

Cardiovascular diseases claimed an estimated 17.9 million lives in 2016 31 per cent of all deaths around the globe.

And 85 per cent of these were due to heart attacks and stroke, most commonly caused by a blockage of the arteries known as atherosclerosis.

Now an international team led by a Cambridge professor of cardiovascular medicine is competing for a 30million prize from the British Heart Foundation to unravel its secrets.

If they beat the other three shortlisted teams in the charitys Big Beat Challenge, they will create the worlds first 3D map of atherosclerosis at single cell resolution, giving unparalleled insight into this hardening or blocking of the arteries.

Prof Ziad Mallat, of the Department of Medicine at the University of Cambridge, tells the Cambridge Independent:We are excited about the prospect of this. We hope we have assembled the right team.

Atherosclerosis is very debilitating. If it happens in the arteries that supply the brain, it causes stroke. If it happens in the arteries supplying the heart, it causes heart attacks.

It is really common across the world. Every five minutes in the UK there is one heart attack and one stroke.

Why is this having such a huge impact on the quality of life of people? We believe something is not being treated or understood.

Clinicians currently treat the risk factors for the disease, which include high blood cholesterol, high blood pressure and diabetes.

What we dont do is really treat what causes the disease, which is the malfunctioning of the immune system, says Prof Mallat.

When you have high blood pressure or cholesterol, this injures the arteries. Initially, the immune system sends immune cells to the injured vessel to try to heal the artery.

However, what we know is that most of the time the immune system doesnt operate properly and this prevents the healing, and so the disease progresses.

We have good understanding of how this happens in pre-clinical models, like mouse models, but very limited understanding of how it happens in humans.

We think this is what is preventing doctors and scientists from finding a treatment that would transform the way patients are treated.

Through their iMap, as they are calling it, Prof Mallat and the team of global experts he has assembled want to understand what is happening in the accumulations, known as plaques, that block the arteries and affect blood flow to the heart and other parts of the body. The plaques can be made up of fat, cholesterol, calcium and other substances.

These plaques obstruct the lumen [the interior space in the artery] and even burst into the lumen, leading to clot formation, which obstructs the blood flow. This causes the heart attacks and strokes, says Prof Mallat.

Our idea is to build the first 3D map of these fatty plaques, at

. We would like to know what each immune cell and each cell in the vessel wall is doing. What is its genetic make-up? What is its protein make-up? What is the fuel that it is using? Why, when the immune cell comes along to do a good job, does it stop doing it?

We want to interrogate each cell and work out how it is interacting and communicating with other cells.

Only with this 3D map of the plaques will we be able to understand what is happening inside. Once we have done this, we will be able to harness this knowledge to find new protective methodologies and therapies.

These therapies could harness the immune system, which raises the possibility of vaccinating against atherosclerosis.

If we understand how the immune cells react, we can use the information to re-educate them with vaccination, suggests Prof Mallat. If they are overreacting to fat components or protein components, we can educate them to make them do the right job when they see this in the arteries, to reduce the inflammation and limit the development of the disease.

The scale of this challenge, however, is vast and requires a multi-disciplinary approach.

It needs a lot of different expertise around the world, says Prof Mallat. You need good cardiologists, good molecular biologists, immunologists, mathematicians and computer scientists because the information will be huge and needs to be integrated together. You need people who know a lot about genomics, lipidomics and proteomics, so we have gathered world-leading experts in each of these areas to come together and look at this problem from every angle possible.

Among those helping Prof Mallat is Sarah Teichmann, from the Wellcome Sanger Institute at Hinxton, who is the co-founder of the global consortium working on the Human Cell Atlas a hugely ambitious and important project creating comprehensive reference maps of all human cells in the human body.

They are looking at the make-up of healthy organs, notes Prof Mallat. Some of the investigators are mapping some of the arteries and are looking at vascular cells like endothelial cells. It is intriguing but nobody else is looking at other cells in the artery. We are looking at both the healthy arteries and the diseased arteries. It is building on the work of the Human Cell Atlas.

Also on the team are experts from Imperial College London, Germany, France, Spain, the La Jolla Institute of Immunology in San Diego and from Icahn School of Medicine at Mount Sinai in New York.

Key to their work is the need for data and samples, and the group has multiple sources available.

We have organ donors from the Cambridge bio-repository and the clinical school at Mount Sinai, so we have access to healthy and diseased arteries from the same individuals.

We have access to blood from these individuals and to immune cells from other parts of the body, so we can compare what the immune cells are doing in different compartments.

The other source is from a cohort of thousands of individuals, through a collaboration with Professor Valentin Fuster in Madrid, who have been followed for more than 10 years, and they will be followed for another 10 years.

We have blood samples and microbiota from them. We also have access to imaging of their arteries. They are followed for cardiovascular outcomes, so if someone has a heart attack or stroke, it is documented.

We will be able to look at the ageing of the immune system in these individuals and how this correlates to changes in their arteries and the occurrence of disease.

All of this is being done at very high resolution, which has not been done before. Integrating the information from the genes, the proteins, the lipids and so on, to have a broad view, has never been possible.

There are parallels with the work being carried out at Cancer Research UK Cambridge Institute under Prof Greg Hannon, where the first virtual 3D tumour is being created using a multi-disciplinary team.

We are discussing with him how we can integrate some of the technologies he is developing. It will be fantastic to collaborate with him on this, says Prof Mallat.

What is known already is that our arteries are sensitive to changes in blood flow.

Even subtle perturbations in the micro-environment are sensed by the arteries and can be considered as a danger, explains Prof Mallat.

When it interprets this as a danger, it sends signals to the immune system to react. I would say this is happening almost continuously, and is aggravated of course when you have additional stimuli like high blood cholesterol or exposure to smoke.

While the use of imaging and monitoring of biomarkers is helping us diagnose atherosclerosis earlier, Prof Mallat describes this as not optimal, because we dont understand the disease in a comprehensive manner. A 3D map would aid diagnosis, prediction and prevention of disease, as well as opening up new therapeutic avenues.

Nobody knew 10 or 15 years ago that the immune system could play such a huge role in cancer, Prof Mallat points out. Now cancer immunotherapy is advancing enormously. We are convinced that atherosclerosis is highly motivated by the immune system but no-one is targeting the immune system to treat it. Thats why we want to understand it and we think this could really induce a revolution in our understanding and how we treat it.

Cambridge Cardiovascular to host events at Cambridge Science Festival

Visitors to Cambridge Science Festival will have a chance to find out more about the iMap project and the work of cardiovascular researchers.

Cambridge Cardiovascular, an umbrella group for the field, is involved in organising activities once again at this years festival, which runs from March 9 to 22.

At 6-7pm on Wednesday, March 18 at the Mill Lane lecture rooms in Cambridge, a talk titled More than a blocked pipe: The hardening of the arteries and their role in stroke and heart attacks will be delivered by Dr Nick Evans, of the Department of Medicine, and Prof Melinda Duer, of the Department of Chemistry.

At 6-7pm on Friday, March 20, also at Mill Lane lecture rooms, Dr Sanjay Sinha, of Cambridge Stem Cell Instituteand the Department of Medicine will discuss Mending broken hearts: stem cells for heart disease.

Then, from 11am to 4pm on Sunday, March 22, A View of the Heart will be on offer at the Cambridge Academy for Science and Technology, in Long Road, where cardiovascular scientists will help you explore the organ and visualise heartbeats.

Book at sciencefestival.cam.ac.uk.

The Big Beat Challenge

The British Heart Foundations 30million Big Beat Challenge is designed as the charitys moon-shot to propel our understanding of cardiovascular disease into a new era.

Some 75 applications were received from 40 countries following its launch in August 2018, and these have been whittled down to four, including the one led by Prof Mallat to map and treat atherosclerosis. The other ideas are:

Hybrid heart

Led by Jolanda Kluin, professor of translational cardiothoracic surgery at the University of Amsterdam in the Netherlands, this team plans to create a solution for heart failure by developing a soft robotic heart. They intend to design, build, test and implant a hybrid heart that consists of a soft robotic shell forming the soft artificial muscles and sensors to enable natural motion, and a tissue-engineered lining to make sure all the surfaces in contact with blood are safe. With wireless energy transfer, the vision is that this could replace the need for human heart transplantation.

Echoes

Led by Professor Frank Rademakers, chief medical technology officer at University Hospitals Leuven, Belgium, this team would develop wearable technology that can be used in daily life to capture more data than ever before. This information ranging from symptoms and physical activity to heart function and air quality could be used alongside genetic and healthcare data to transform diagnosis, monitoring and treatment of heart and circulatory diseases through the creation of a digital twin.

Cure heart

This project aims to provide a cure for inherited, killer heart muscle diseases. Led by Professor Hugh Watkins, BHF chair of cardiovascular medicine at the University of Oxford, these researchers will develop a treatment that targets and silences the faulty genes responsible for cardiomyopathies diseases of the heart muscle that can lead to sudden death at an early age. They intend to combine a deep understanding of underlying genetic mechanisms with new technologies, to stop the progression of the damage caused by genetic heart muscle diseases, or even reverse the damage.

Professor Sir Nilesh Samani, medical director at the British Heart Foundation, said: Heart and circulatory diseases remain the number one cause of death worldwide.

Were taking small steps forward every year but whats needed is a giant leap, which wont be achieved by a business-as-usual approach.

The Big Beat Challenge embodies our ambition to turbo-charge progress and could lead to its own man on the moon moment. I have absolutely no doubt the winning idea will define the decade in their area.

The teams will prepare their final applications by June 14, with interviews in early September and a decision expected by the end of the year.

Read more

Our guide to the Cambridge Science Festival 2020

Can HIV be cured? Evelyn Trust-funded research at University of Cambridge probes viral latency

Inside the Cambridge lab in pole position to create a new coronavirus vaccine

Sanger Institute scientist helps unveil blueprint for extraordinary Human Cell Atlas

Prof Greg Hannon on taking over at the Cancer Research UK Cambridge Institute and creating the worlds first virtual reality tumour

Read the original here:
Prof Ziad Mallat leads Cambridge effort to win 30m to tackle leading cause of heart attacks and strokes - Cambridge Independent

Read More...

Induced Pluripotent Stem Cells Created from Fat Cells …

Tuesday, March 3rd, 2020

The standard way to make induced pluripotent stem (iPS) cells for medical research is to scrape skin cells and mix up their internal clocks, coaxing them back into pluripotency over a matter of weeks. But now researchers at the Stanford University School of Medicine have turned their attention to another cell type in abundant supply: fat cells. The team of cardiologists and plastic surgeons found adipose fat cells to be much more efficient than skin cells at turning back into stem cells.

The potential of iPS cells to help treat everything from damaged heart tissue to Parkinson's disease, has prompted intensive research that has looked into the use of skin fibroblast cells as an alternative to controversial embryonic stem cells. Skin cells, however, take a few weeks to be cultured into pluripotencya process that also often requires exposing the cells to mouse stem cells, called feeder cells, to nourish and guide the transformation.

"We thought, why not use a different cell typeand we can easily get access to fat," says Joseph Wu, a co-author of a study on this process and assistant professor of medicine at Stanford. Fat also "turns out to be a readily available, great natural resource," says Michael Longaker, a professor of plastic surgery at Stanford. He and Wu point out that more than a third of Americans are considered obese and even young, healthy patients would have ample fat to harvest for iPS cell culturing. Each liter of fat promises hundreds of millions of potential cells, Longaker estimates.

Other stem cells in the body, such as liver and stomach cells, have been examined for their ability to culture usable iPS cells. Fat stem cells, however, seem especially primed for the job, as they are capable of turning into fat, heart, bone or muscle tissue. "We know that these fat cells are multipotent, which should [make it] easier to reprogram them," Wu says.

Indeed, they were: According to the team's findings, adipose stem cells can be turned into iPS cells twice as quickly as fibroblast skin cells and with 20 times the efficiency. The process can begin immediately after the fat is harvestedvia liposuctionand cells are ready to culture within the same day.

The results were published online today in Proceedings of the National Academy of Sciences.

Wu and Longaker, both clinical practitioners, are always looking for methods that will present "one less hurdle to worry about," Longaker says. Being able to skip the mouse feeder cell step necessary with skin cells, along with the shortened culturing period, may make the new method more palatable to the U.S. Food and Drug Administration (FDA), which must approve such treatments for human use and prefers methods that reduce opportunities for contamination.

Wu, Longaker and their team still have many questions to answer before fat cells could become the latest industry iPS cell standard. They need to find out how much differentiation these cells require before they become helpful in specific areas of the body. "How much do you have to coach them in the dish before you put them back in the patient before they become heart muscles, say?" asks Longaker.

The ultimate safety of the cells, especially regarding their potential to spark cancer, will also need to be examined in more detail, notes Yasuhiro Ikeda, an assistant professor of molecular medicine at the Mayo Clinic's College of Medicine, in Rochester, Minn., who wasn't involved in the work. "It will be necessary to characterize the cells in more detailfor their tumorigenicity upon transplantation," he wrote in an email.

Wu and Longaker's research thus far has taken a fairly broad swipe at reprogramming adipose fat stem cells, so the team hopes to refine the process to target only the most efficient candidates. "If these are a so-called chicken soup of [cell] population, we dont know if it's one type of cell or five," Longaker says. "We would like to identify which sub-population is most easily reprogrammableand reprogram it in a way the FDA would approve of."

Other researchers in the field will be watching to see what further tests might reveal about the practicality of using fat cells instead of skin cells for iPS research. "This is definitely a promising new technology for iPS, particularly translating this technology into the clinic in the future," Ikeda notes.

Here is the original post:
Induced Pluripotent Stem Cells Created from Fat Cells ...

Read More...

Stem Cells from Fat vs. Bone Marrow – Best Sources for …

Tuesday, March 3rd, 2020

Stromal vascular fraction was dramatically better than bone marrow concentrate in its ability to differentiate into cartilage.Two other important features were also well documented in this study. SVF created significantly more colony forming units than BMC, another significant predictor of healing response. Perhaps most importantly, SVF was dramatically better than BMC in its ability to differentiate into cartilage.

Second, a study by Han Chao et al has also demonstrated that fat derived stem cells also have a higher proliferation potential for neural tissue and are a better source for not only cartilage regeneration but also for nervous system regeneration.

The studies gave a very comprehensive look at comparing BMC and SVF in the ability to repair cartilage damage in a same procedure protocol. Every significant measurement comparing bone marrow to adipose tissue for stem cell harvesting demonstrated that adipose derived stem cells provided better cell content and superior ability to differentiate into cartilage than bone marrow. Our extensive clinical experience with the procedure for Colorado patients suffering from pain in the knees, other joints, soft tissue, and a wide range of back problems clearly demonstrates the same.

Using the most effective combination of autologous stem cell sources is one of several criteria to identify a legitimate stem cell clinic. Other important characteristics we recommend paying attention to when choosing a stem cell clinic, include the presence of a physician who owns and operates the clinic, X-ray guided injections administered by a trained injection specialist, and a clinic that takes time to discuss your questions. A review of your imaging and clinical data is needed in order to determine if stem cell therapy is right for you.

*Individual patient results may vary. Contact us today to find out if stem cell therapy may be able to help you.

See original here:
Stem Cells from Fat vs. Bone Marrow - Best Sources for ...

Read More...

MAX BioPharma Announces Key Update to its Liver Fibrosis Program Showing Efficacy of an Oxysterol Lead Drug Candidate in Inhibiting NASH in a…

Tuesday, March 3rd, 2020

MAX BioPharma is Pursuing Strategic Partnerships and Series A Financing

LOS ANGELES, March 3, 2020 /PRNewswire/ --MAX BioPharma, Inc. (www.maxbiopharma.com) recently published an article describing its anti-tumorigenic oxysterol lead compound, Oxy210, in the peer-reviewed journal, Cells. (https://www.mdpi.com/2073-4409/8/10/1297/pdf). Oxy210 is derived from the Company's Oxysterol Therapeutics platform of proprietary oxysterols. Oxy210 was shown to inhibit two key cellular pathways, Hedgehog and transforming growth factor beta (TGFb), which play important roles not only in cancer but also in driving pathologic fibrosis in a number of organs including liver, lung and kidney. Oxy210 has unique mechanisms of action compared to other Hedgehog and TGFb signaling inhibitors that are commercially available or under clinical development. This new drug candidate is orally bioavailable, has favorable pharmacokinetic and safety profiles, is scalable, and was found to inhibit activation and pro-fibrotic activities of human liver stellate cells that drive fibrosis.

In a recent 16-week study conducted at UCLA under the direction of Drs. Jake Lusis and Simon Hui, Oxy210 was found to significantly inhibit development of fibrosis in a humanized mouse model of non-alcoholic steatohepatitis (NASH) that involves progressive inflammation, fat deposition and fibrosis in the livers of these mice. The inhibition of fibrosis involved inhibited expression of TGFb, NLRP3 inflammasome, and inflammatory cytokines: interleukin-6 (IL-6), tumor necrosis alpha (TNF-a), and monocyte chemotactic protein 1 (MCP-1) in the liver and plasma of mice that consumed Oxy210 incorporated in their food. Moreover, Oxy210 inhibited lipid deposition, including total cholesterol, unesterified cholesterol, cholesterol ester, and phospholipids in the livers of the hyperlipidemic mice.

"There is an urgent need for therapies to treat fatty liver disease, and I find the results of our studies with MAX BioPharma quite exciting," states Dr. Lusis, Principal Investigator and Professor of Medicine, Human Genetics, Microbiology, Immunology & Molecular Geneticsat UCLA.

"Our humanized hyperlipidemia mouse model of NASH reflects the natural history of non-alcoholic fatty liver disease (NAFLD) progression in humans and reproduces the salient features of human NASH. Attenuation of hepatic fibrosis and inflammation by Oxy210 suggest that it could be a promising therapeutic for human NASH," explains Dr. Hui, Project Scientist and Co-Principal Investigator at UCLA.

"Evidence that the Hedgehog-TGFb inhibitor, Oxy210, improves liver inflammation and fibrosis in the mouse model of NASH is encouraging given growing evidence that these signaling pathways critically control liver repair and are dysregulated in patients with NASH, cirrhosis and primary liver cancer," states Dr. Anna Mae Diehl, Florence McAlister Distinguished Professor of Medicine at Duke University.

MAX Biopharma is currently optimizing oral dosing with Oxy210 and performing pre-clinical studies required by the FDA for clinical development and commercialization, and is seeking strategic partnerships with biotechnology and pharmaceutical companies that have the expertise and resources to further the development of oxysterols towards FDA approval and commercialization. In addition, MAX BioPharma is in the process of raising a series A financing round to support the advancement of its therapeutic development programs. "We are very excited and hopeful that our efforts will result in an effective and safe therapy for NASH that will significantly improve the lives of those affected by this currently incurable disease" says Dr. Farhad Parhami, Founder, President and CEO of MAX BioPharma.

About MAX BioPharma, Inc.

MAX BioPharma is a privately-held preclinical stage California-based biopharmaceutical company developing novel small molecule lipids as drug candidates for intervention in debilitating and fatal human diseases. The company will be a leader in a new field of Oxysterol Therapeutics by leveraging a robust and growing intellectual property portfolio that will lead to treatments for numerous indications. MAX BioPharma's first success based on small molecule lipids has contributed to the discovery of novel osteogenic oxysterol compounds that target multipotent mesenchymal cells, including mesenchymal stem cells, to induce the formation of bone-forming osteoblasts and bone. The company is translating this technology into the next generation of therapeutic agents for stimulation of bone formation, locally and systemically, in indications such as spinal fusion, non-union fractures, and osteoporosis. MAX BioPharma is also pursuing the development of small molecule oxysterols that function as anti-tumorigenic Hedgehog and TGFb pathway antagonists that will be more effective than currently known antagonists in treating a variety of cancers, including lung and pancreatic cancer, and hematologic malignancies, as well as fibrotic diseases of liver, lung, and kidney among others. For more information please visit us at http://www.maxbiopharma.com

Media Contact: Farhad Parhamifparhami@maxbiopharma.com

View original content:http://www.prnewswire.com/news-releases/max-biopharma-announces-key-update-to-its-liver-fibrosis-program-showing-efficacy-of-an-oxysterol-lead-drug-candidate-in-inhibiting-nash-in-a-humanized-mouse-model-301015161.html

SOURCE MAX BioPharma

See the article here:
MAX BioPharma Announces Key Update to its Liver Fibrosis Program Showing Efficacy of an Oxysterol Lead Drug Candidate in Inhibiting NASH in a...

Read More...

Doctors Are Injecting This Naturally-Derived Substance to Restore Hair Thicknessand Its Not PRP – NewBeauty Magazine

Wednesday, February 26th, 2020

The most emotional issue my patients have is hair loss, says New York dermatologist Cheryl Karcher, MD below a jaw-dropping before-and-after photo shared to her Instagram page. On the left half of the photo shared is a young womans exposed hairlinethe hair is so thin and sparse, the entire scalp is visible wherever your eye is drawn. On the right side of the photo, the same woman, but with an almost unbelievable amount of thicker hair, and, somehow, a sense of renewed confidence.

The secret? A little thing called nanofat.

In the past we only had PRP to offer that had to be done three times or more. Sometimes it would work, sometimes it didnt. Now we have nanofat hair restoration, which needs to be done just once, and is much more effective way to treat hair loss and grow hair, explains Dr. Karcher.

You May Also Like: How Low Level Laser Therapy Actually Works to Thicken Hair

So what is nanofat? According to Dr. Karcher, its derived from our own adipose tissue, whereas the ever popular PRP is derived from our blood. Nanofat includes adipose-derived stromal vascular fraction, which contains stem cells as well as growth factors. PRP contains the growth factors released from platelets in the blood, she adds. The procedure itself involves extracting anywhere from 20 to 40 millilitersof fat, usually from the abdomen, then processing it through mechanical filters, before injecting.

Like PRP, the possibilities of what nanofat can help with doesnt stop at the hairline. After the nanofat is processed to the point where there is no fat left, only stem cells and growth factors, it is injected into the scalp, the face, the neck, the decollete, or to improve sun damage, skin pigmentation, decrease wrinkles, and of course grow hair, says Dr. Karcher.

When nanofat is used for hair restoration, Dr. Karcher says she first injects the nanofat, then injects the patients PRP on top of it to act as a fertilizer for the nanofat. Perhaps the best part? Theres little to no painDr. Karcher says the most pain patients feel is during the PRP injections, so the scalp is numbed topicallyand no downtime. When nanofat is used on the face, chest or other areas, Dr. Karcher warns there may be some downtime of erythema and swelling or bruising. If injected for [skin] rejuvenation via microneedling the downtime is only about 48 hours.

While Dr. Karcher has seen unparalleled results from nanofat hair restoration, it is only ideal for patients who have some hair still present on the scalppatients who are completely bald may not be ideal candidates for the procedure. The only time I ever use PRP for hair restoration now is in a patient that doesnt have enough fat to harvest. The nanofat is just one treatment and the results seem to be superior. However, as La Jolla, CA plastic surgeon Robert Singer, MD notes, there is no safety or efficacy data surrounding nanofat treatment as of press time.

Sign up to receive our newsletter

Read more:
Doctors Are Injecting This Naturally-Derived Substance to Restore Hair Thicknessand Its Not PRP - NewBeauty Magazine

Read More...

Experimental study speeds up bone healing with 2 common medications – New Atlas

Monday, February 24th, 2020

A new proof-of-concept study has found a combination of two drugs, already approved by the FDA for other uses, may boost the release of stem cells from bone marrow and accelerate the healing of broken bones. Only demonstrated in animals at this stage, the researchers suggest clinical trials could progress rapidly considering the drugs have already been demonstrated as safe in humans.

"The body repairs itself all the time, says corresponding author on the study Sara Rankin. We know that when bones break they will heal, and this requires the activation of stem cells in the bone. However, when the damage is severe, there are limits to what the body can do of its own accord.

A great deal of current research is focusing on mesenchymal stem cell (MSC) therapies. MSCs are a type of adult stem cell that can grow into a variety of different cell types including muscle, fat or bone. Many current MSC treatments in development involve extracting a small number from a patient, growing them in laboratory conditions, then injecting them back into the patient.

The new research set out to investigate whether any currently approved drugs can function to mobilize the bodys natural ability in releasing MSCs, with a view on speeding up healing of bone fractures. A study published in the journal npj Regenerative Medicine, describes the testing of two already approved drugs in a rodent spinal injury model.

The two drugs tested were an immunostimulant called Plerixafor, used to stimulate the release of stem cells from bone marrow in cancer patients, and a beta-3 adrenergic agonist developed to help bladder control.

The results suggest the duo of drugs mobilize MSCs into the bloodstream and speed up the process of bone formation and healing by enhancing the binding of calcium to the injury site. Tariq Fellous, first author on the new study, suggests the next step is to investigate whether this drug combination enhances blood MSC levels in human subjects.

We first need to see if these medications release the stem cells in healthy volunteers, before we can then test them in patients with fractures, says Fellous. We have the drugs and know they are safe to use in humans - we just need the funding for the human trials.

The researchers say prior studies have identified circulating MSCs increase in volume following injuries such as burns, bone fractures, and even heart attack. The hypothesis is that the release of MSCs is a physiological process aiding general regeneration following injury, and if circulating numbers of MSCs could be pharmacologically enhanced then a variety of types of tissue regeneration could be accelerated.

It is important to note the current study only examined increases in circulating MSCs and the rate of spine injury healing compared to no drug treatment. The current research offers no indication whether the drug duo influences nerve healing or restores movement.

So, more work is certainly necessary to understand how clinically useful these results actually are. However, as the studys co-first author Andia Redpath notes, this re-purposing of existing medicines to boost stem cell activity is an easier, cheaper, and more efficient way to enhance healing compared to other, more complex and time-consuming, stem cell treatments in development.

Rather than devising new stem cell treatments from scratch that involve lengthy and expensive trials, our approach harnesses the power of the bodys own stem cells, using existing drugs, says Redpath. We already know the treatments in our study are safe, its now just a matter of exploring further if they help our bodies heal.

The new study was published in the journal npj Regenerative Medicine.

Source: Imperial College London

Excerpt from:
Experimental study speeds up bone healing with 2 common medications - New Atlas

Read More...

Switch Up Heart Cell Diet To Help Regeneration – Technology Networks

Monday, February 24th, 2020

Switching what the powerhouses of heart cells consume for energy could help the heart regenerate when cells die, a new study led by UTSouthwestern researchers suggests. The finding, published in the Feb. 20, 2020,Nature Metabolism, could open whole new avenues for treating a variety of conditions in which heart muscle becomes damaged, including heart failure caused by viruses, toxins, high blood pressure, or heart attacks.

Current pharmaceutical treatments for heart failure including ACE inhibitors and beta blockers center on trying to stop a vicious cycle of heart muscle loss as strain further damages remaining heart muscle, causing more cells to die, explains UTSouthwestern physician-researcher Hesham A. Sadek, M.D., Ph.D., the J. Fred Schoellkopf, Jr. Chair in Cardiology. There are no existing treatments for rebuilding heart muscle.

Nine years ago, Sadek and his colleagues discovered that mammalian hearts can regenerate if theyre damaged in the first few days of life, spurred by the division of cardiomyocytes, the cells responsible for a hearts contractile force. However, this capacity is completely lost by 7 days old, an abrupt turning point in which division of these cells dramatically slows.

Subsequent research has shown that this change in regenerative capacity appears to stem, at least in part, from damaging free radicals generated by organelles known as mitochondria, which power cells. These free radicals damage cells DNA, a phenomenon called DNA damage, which prompts them to stop dividing.

The shift in free radical production appears to be spurred by a change in what mitochondria in the cardiomyocytes consume for energy, Sadek explains. Although mitochondria rely on glucose in utero and at birth, they switch to fatty acids in the days after birth to utilize these energy-dense molecules in breast milk.

Sadek and his colleagues wondered whether forcing mitochondria to continue to consume glucose might stymie DNA damage and, in turn, extend the window for heart cell regeneration. To test this idea, the researchers tried two different experiments.

In the first, they followed mouse pups whose mothers were genetically altered to produce low-fat breastmilk and that fed on low-fat chow after they weaned. The researchers found that these rodents hearts maintained regenerative capacity weeks later than normal, with their cardiomyocytes continuing to express genes associated with cell division for a significantly longer window than those fed a diet of regular breastmilk and chow. However, this effect didnt last into adulthood their livers eventually made up the deficit by synthesizing the fats that their diets were missing, which significantly reduced their hearts regenerative capacity.

In the second experiment, the researchers created genetically altered animals in which the researchers could delete an enzyme, known as pyruvate dehydrogenase kinase 4 (PDK4), necessary for the heart cells mitochondria to digest fatty acids. When the researchers delivered a drug to turn off PDK4 production, the animals cardiomyocytes switched to consuming glucose instead of fatty acids, even in adulthood. After researchers simulated a heart attack, these animals experienced improvement in heart function, which was accompanied by markers in gene expression that suggested their cardiomyocytes were still actively dividing.

Sadek notes that these findings provide proof of principle that its possible to reopen the window for heart cell regeneration by manipulating what cardiomyocyte mitochondria consume for energy.

Eventually, he says, it may be possible to develop drugs that change what cardiomyocytes eat to make them divide again, reversing heart failure and representing a true cure.

Reference: Cardoso et al. (2020).Mitochondrial substrate utilization regulates cardiomyocyte cell-cycle progression. Nature Metabolism. DOI: https://doi.org/10.1038/s42255-020-0169-x.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read more here:
Switch Up Heart Cell Diet To Help Regeneration - Technology Networks

Read More...

Dubai is the ‘new Beverly Hills of the Middle East’: Here’s why – Gulf News

Monday, February 24th, 2020

Image Credit: Getty Images/iStockphoto

Dubai: It's an industry on the rise, driven by social media before-and-after ads.

And it's ramping up the speed by which Dubai is fast becoming the "new Beverly Hills of the Middle East."

Already, cosmetic surgery has topped the list in medical tourism in Dubai. According to a Dubai Health Authority (DHA) report, the emirate has the highest number of cosmetic surgeons per capita in the region about 50 specialists for a million people.

It's a huge market.And a money-spinner: Price ranges from Dh150-250 for a filler to Dh40,000 for a detailed body sculpting procedure.

Globally, the cosmetic surgery market size is projected to reach $21.97 billion with 7.8% annual growth rate by 2023, according to a Medgadget report.

These are the most common surgery options:

To put this in perspective, we talked to several people.

Myra J., a belly dancer working at a Dubai hotel. She was unhappy. Saddle bags on her thighs were making her performance less graceful. She honestly feared she would be jobless soon.

On a weekend, she checked into a leading aesthetic clinic and the surgeon trimmed the pockets of fat around her thighs, sculpting her body back into perfect shape.

It took her a week to recover and get back to work, but she is delighted with her shapely thighs and feels happier than ever before.

'Ageing gracefully'

Nina M., (52), always loved how beautiful her eyes were and how youthful her cheeks looked.

Last year, nowever, as she got busy with her sons marriage preparations, she started to experience bouts of anxiety at the sight of slowly encroaching bags under her eyes and a slight droop in her cheeks.

I wanted to look and feel my best and thought a filler and a round of botox were harmless indulgences. It took me just an hour at the clinic and the results were amazing. I am glad I was able to stop the onslaught of aging in time.

"Its beautiful to age gracefully, but we all do use creams and gels to delay the process. I think of these minor injectibles as tools in our make-up bag.

"I have used fillers and Botox twice since last year, combined with my beauty regimen. I feel it has given me not just confidence but also psychological boost. I would recommend it to everyone.

Anna M was a physical trainer but vexed with her body shape as she had a masculine build.

- Anna M, a physical trainer

This was affecting her work. Most women were intimidated by her personality and she was losing self-confidence.

Four years ago, she went in for breast implants and her life changed.

Addiction to surgery?

People talk about getting addicted to cosmetic surgery. But that is not so. Most people approach a cosmetic surgeon only when they cannot deal with a physical issue themselves and just like one needs medicine when one is ill, cosmetic surgery acts as a solution to boost confidence and self-esteem.

"Look at how people have reclaimed their health with gastric bypass!

- Dr Sanjay Parashar, chairman, Scientific of the Emirates Plastic Surgery Society

Changing the world one person at a time and providing them with an incredible burst of confidence, aesthetic and cosmetic surgeons in the UAE have built a practice of reliability that can take as little as one hour to a day to transform your personality.

Welcome to the multi-million dirham cosmetic surgery industry in the UAE.

It is the toast of medical tourism in the region, with a high footfall of Gulf and Asian medical tourists as well as resident expatriates.

The industry has accelerated at a speed that is making Dubai be hailed as the new Beverly Hills of the Middle East.

Cosmetic or Plastic Surgery?

These are two different concepts. Cosmetic surgery refers to aesthetic surgery and revolves around enhancement of physical features of an individual and is elective.

This includes procedures such as:

Plastic surgery, on the other hand, is a surgical speciality dealing with life-saving procedures of re-construction of the face and body owing to congenital defects, disfigurement due to accident, trauma, burns, tumour removal due to diseases such as cancer.

In most cases, plastic surgery is not elective.

Dh12b Medical tourism sales in 2018

Since the time pop stars began to inundate Instagram with images of their perfect bodies, dazzling smiles, flawless skin and enviable hair volume, elective procedures have become commonplace with teenagers as young as 13 who are going in for instant fixes.

While some procedures require a couple of days of hospital stay and being out of circulation for a while, many quick fixes are carried out during lunch breaks in one-hour durations.

Highest per capita cosmetic surgeons in UAE

Dr Sanjay Parashar, chairman, Scientific of the Emirates Plastic Surgery Society, told Gulf News: Cosmetic surgery tops the list in medical tourism in Dubai and according to a 2015 report of Dubai Health Authority (DHA), Dubai has the highest number of cosmetic surgeons per capita in the region about 50 specialists for a million people.

- Dr Zuhair Al Fardan, President of the Emirates Plastic Surgery

Dr Parashar added: The field has grown beyond expectations and much of the credit goes to the development of a world-class infrastructure in this field and the corresponding health regulations.

"Today, in Dubai, most Day Care Surgery centres where most of the plastic surgery procedures are carried out have the best international accreditations.

Dr Zuhair Al Fardan, President of the Emirates Plastic Surgery, said: Much of the advancement in plastic and cosmetic surgery is work in progress as surgeons are constantly upgrading themselves with techniques, technologies.

The UAE is keeping abreast of the best that is taking place in the world. In the last five years or so, there have been tremendous advancements in cosmetic and plastic surgery in the UAE.

BEVERLY HILLS AND PLASTIC SURGERY

It's where leading practitioners are rated by customers who give feedback and grade their experience with plastic surgeons according to a five-star rating system.

In this posh district, located within 5.7 square miles and surrounded by the cities of Los Angeles and West Hollywood, one of most popular procedures is breast augmentation, according to online directory and crowd-sourced review forum Yelp.

"We have the top plastic surgeons of the world come here to do surgeries and the UAE hosts two major international plastic surgery conferences each year.

Soaring revenues

With greater acceptance and broadening of scope for the discipline, it is evident that plastic surgery is a major revenue earner and places UAE as one of the leading medical tourism destinations in the region.

From a price range of Dh150-250 for a filler to Dh40,000 for a detailed body sculpting procedure, these procedures are money-spinners.

Together, the plastic and cosmetic surgery is a multimillion dirham business in the UAE. While there are no exact figures available, safe estimates can be made, say surgeons.

MULTIMILLION BUSINESS

There are 30 hospitals in Dubai, of which 70 per cent are internationally accredited. The emirate aims to build 22 hospitals by 2020 18 private and 4 public hospitals.

In Dubai, at least 50 per cent of its 30 hospital offer cosmetic and plastic surgery options.

30 number of hospitals in Dubai, of which 70 per cent are internationally accredited

Besides that there are about 150 Day Care Surgery centres and 400 aesthetic clinics in Dubai.

All of them offer a bouquet of cosmetic surgery procedures and their average annual revenue is between Dh4-6 million a year.

400 Number of aesthetic clinics in Dubai

If one were to compute that with the numbers of facilities including hospitals, the annual revenue from cosmetic surgery would run into many millions of dirhams annually.

High on medical tourism

Currently, Dubai aims to attract 500,000 medical tourists a year by end 2020.

In a short priod of time, Dubai has managed to be ranked 17 among the top 25 global destinations for medical tourism and cosmetic surgery, along with fertility, orthopaedic, dental and wellness disciplines in the list of most-billed medical procedures.

40% percentage of tourists who come to Dubai come only for medical tourism. Medical tourism sales topped Dh12 billion in 2018, a 5.5% jump in the number of medical tourists

Based on official data, about 46 per cent of the current medical tourists in Dubai come from Asian countries. About a quarter (25 per cent), come from GCC and Arab countries and 13 per cent from African countries, and the remaining 16 per cent from other countries, mainly the UK and Commonwealth of Independent States (CIS) countries.

In fact, 40 per cent of tourists who come to Dubai come only for medical tourism.

- Dr Francis Conroy, consultant plastic, cosmetic and reconstructive surgeon at the American Hospital, Dubai

Medical tourism sales topped Dh12 billion in 2018, with a 5.5 per cent overall increase in medical tourists.

Medical tourists

Dubai attracted a total of 640,542 international and domestic medical tourists in 2018 (51 per cent were international patients).

European tourists consisting mostly of UK, French and Italian citizens, share 16 per cent of health and wellness tourists.

A substantial medical tourism revenue, it is evident, is earned through plastic and cosmetic surgery.

Dr Francis Conroy, consultant plastic, cosmetic and reconstructive surgeon at the American Hospital, Dubai, remarked: American Hospital Dubai, is one of the few facilities offering both comprehensive reconstructive and cosmetic surgery services.

"Our plastic surgeons are fully trained in both reconstructive and cosmetic surgery so we see a wide-ranging case mix, from severe trauma cases to cancer cases and of course, those opting for cosmetic surgery."

Most popular cosmetic surgery

Typically, these patients would be female, who done with having children and raising them, now wish to address the changes in their body. I also see a large number of male patients who want to correct problems associated with their chest with the help of liposuction.

Source: Dr Francis Conroy, consultant plastic, cosmetic and reconstructive surgeon at the American Hospital, Dubai

Most popular cosmetic surgery

"Typically, these patients would be female, who done with having children and raising them, now wish to address the changes in their body. I also see a large number of male patients who want to correct problems associated with their chest with the help of liposuction, said Dr Conroy.

Non-surgical treatments (neuro-modulators, fillers, etc) are still very popular and I have seen a trend in that patients are starting with such treatments at an earlier age.

Given the prestigious reputation of the hospital and the Dubai governments plan to promote medical tourism, I have noticed a huge influx of patients from Africa, Nigeria and Ghana in particular.

"These patients come mainly for cosmetic surgery, knowing that they are in the hands of a highly qualified surgeon, in a safe, luxurious facility, with standards second to none, said Dr Conroy.

Top six cosmetic surgery procedures in town

The procedures can be divided into categories:

Does health insurance cover plastic surgery?

"Reconstructive surgery such as correction of birth deformities such as a tuberous breast, cleft lip, hand deformities, skin transplant following burns, road trauma and breast augmentation and reconstruction following a mastectomy and rebuilding after a tumour resection is all covered under all leading health insurances. There is also new kinds of stem cell therapy being used to regenerate tissues and nerves especially in diabetic patients.

Know the rules:

The DHA has made it mandatory for all Day Care Surgery Centres, most of who carry out aesthetic procedures, to have one leading international accreditation from Canada, US, UK or Australia.

These accreditations were earlier mandatory for hospitals only, but from 2020, all Day Care Surgery centres compulsorily must have an international accreditation.

This ensures that an independent, international medical body enforces global health standards to grant them certification and in case of a sentinel event, conducts its independent inquiry and downgrades these places in case of a serious lapse.

DHA on its own has issued a 25-page manual on quality and regulations that is to be followed at all centres.

A close examination of the Day Care Surgery centres indicates several layers of quality control.

Pre surgery quality

This involves free consultation, especially in case of a second opinion or a first time patient seeking to enquire about a procedure based on his/her requirement. When a patient uploads a request on the website of a centre from anywhere in the world, the centre has to provide a detailed consultation free of charge.

Services available to a patient

Once the patient is convinced and comes in person to consult the doctor, quality is upheld in the pre-diagnostic tests that the patient has to undergo.

Infrastructure quality

DHA has graded Day Care Centres into A, B and C categories based on the level of medical facilities that can be accessed by a patient. Anaesthesia methods such as oral, epidural and general also help classify centres. For instance, hair transplant procedures can only be carried out in B and above grade clinics. Day Care Centres that conduct surgeries under general anaesthesia much be equipped with the Advance Cardiac Life Support (ACLS) with their surgeons and registered nurses being certified as trained in administering ACLS to a patient.

Patient safety protocol

There are very specific guidelines for patient safety and the doctor/surgeon must explain the procedure in detail to the patient and his/her family and obtain a written consent to go ahead after ascertaining that all risks and side-effects have been clearly explained to the patient.

See the rest here:
Dubai is the 'new Beverly Hills of the Middle East': Here's why - Gulf News

Read More...

Will Cultured Meat Soon Be A Common Sight In Supermarkets Across The Globe? – Forbes

Monday, February 17th, 2020

A hamburger made out of cell-based meat by Mosa Meat, one of many companies throughout the world ... [+] creating beef and other animal products without the animal.

Up until now, plant-based food companies like Beyond Meat, Impossible Foods, and Quorn have almost singlehandedly worked to lessen the impacts of industrial animal agriculture.

Supermarket shelves and fast food restaurants across the US are serving up vegan burgers and meatballs and plant-based chicken nuggets are showing consumers there is an alternative to relying on animal-based protein.

But a quiet revolution is also taking place in labs, where scientists are working to cultivate meat and seafood grown from cells, with the potential to reduce demand for industrial animal agriculture even further.

Heres how the process works: Stem cells are taken from the muscle of an animal, usually with a small biopsy under anesthesia, then theyre put with nutrients, salts, pH buffers, and growth factor and left to multiply. Finessing the technology and getting the cost to an affordable level is happening at a slower pace than the plant-based industry, but a number of start-ups are nevertheless aiming to get their products on the market soon.

Memphis Meats' pan-seared cell-based chicken with sugar snap peas.

Cell-based meat (also known as cultured, cultivated, slaughter-free, cell-cultured, and clean meat) could be a common sight in supermarkets across the west in the next three years, according to theInstitute of the Future in Palo Alto. California-based Memphis Meats made headlines for its world-first cell-based meatballs four years ago, and iscurrently building a pilot plantto produce its cultured beef, chicken, and duck on a bigger scale with plans to launch more plants around the world.

And it isnt the only cell-based meat start-up in the The Golden State. Theres the recently formed San Francisco-basedArtemys Foods, co-founded by biochemist Jess Krieger, who has spent the past six years working at Kent State University in Ohio growing cell-based meat in a lab, Berkeley-basedMission Barns, focusedon creating animal fat, which it has mixed with other ingredients to make duck sausages, and San Diego-based BlueNalu, a startup developing seafood from fish cells through a process called cellular aquaculture.

Close up of BlueNalu's whole-muscle, cell-based yellowtail, beer-battered and deep-fried for fish ... [+] tacos.

But innovation isnt limited to the US its happening across the world.The global cell-based meat market is predicted to be worth$15.5m by 2021 and $20m by 2027,according to analysis.One report estimates that35% of all meat will be cultured by 2040.

While estimates vary, one study found that cell-based beef is projected to use 95 per cent fewer global greenhouse gas emissions, 98 per cent less land use and up to half as much energy. It also significantly reduces the amount of antibiotics needed, which are widely used in agriculture and contribute hugely to worseningantibiotic resistance. And since the animal cells are extracted humanely and grown in a facility rather than within the animals themselves, cell-based meat has the potential to all but eliminate animal suffering.

The industry has made huge progress since the first cell-based hamburger was unveiled in 2013 in London byDutch stem cell researcher Mark Post, chief scientific officer atDutch companyMosa Meat.While this was a huge achievement, it also showed the world how far the industry had to go before commercially viable cell-based meat could be a reality. It cost $325,000 to make, and wasnt totally animal-free, as most of the burgers muscle strands were grown with fetal bovine serum, which comes from blood drawn from bovine fetuses.

In the intervening years, Mosa Meat has made several breakthroughs, and aims to bring the price down to a commercial price. It now doesnt require fetal bovine serum, and hasdeveloped a process thatallows industrial scale production.

Cell-based tartar (raw minced beef, commonly eaten in some of the Northern European countries), ... [+] created by Mosa Meat.

Also in the Netherlands, start-up Meatable has recently raised 9m to help reduce costs and scale-up production of its beef and pork. It aims to havean industry-scale plant by 2025,and will have a small-scale bioreactor the machine where cell-growth takes place - this year.Meatables cofounder Krijn de Nood hopes tounveil its first prototype this summer.

Elsewhere in Europe, the UKs Higher Steaks is growing stem cells for the production of mince for pork sausages. Instead of using fetal bovine serum,the company uses protocols exclusively licensed to itby its collaborators, the University of Minnesota, that allow it to reprogram stem cells into muscle and fat tissues.

Instead of adult stem cells, it uses induced pluripotent stem cells, which means they have an infinite supply as the cells proliferate infinitely. With adult stem cells, researchers have to go to the animal every time they need a new batch.

AndSpains Cubiq Foodsis producing cell-based fat, which is used to enhance the flavor of food and enrich it with essential fatty acids, such as omega-3.

But when it comes to cell-based meat, all eyes are on Israel, where a number of start-ups likeFuture Meat Technologies and SuperMeat are making huge progress. The countrys interest in cell-based meat has also been attributed to its thriving vegan culture.

Comparison of Future Meat Technologies' cell-based chicken (left) to of farm-raised chicken (right). ... [+]

Future Meat Technologies, founded in 2018, has shortened the manufacturing process to two weeks, with a patent-pending method they say allows for higher production yields of cell-based beef. The start-up's technologies enable producers, farmers and retailers to manufacture biomass and process it locally. The company hopes toget cost down to $10 per poundby 2022.

As for SuperMeat, it is developing cell-based meat from chicken cells (it claimed during its launch in 2016 that it wasthe first company to work on clean chicken productsfor mass production). One of Europe's largest poultry producers,PHW-Gruppe formed a partnershipwith SuperMeat in 2018. We believe 2020 will be the tipping point for the cultivated meat industry, once the proof of scale will be introduced to the world, says Shir Friedman, Co-Founder and Chief Communications Officer of the company. SuperMeat is excited to take a lead part in this historical event."

An illustration of SuperMeat's cell-based meat cultivators of the future.

Another Israeli start-up,Aleph Farms, created the worlds first cell-based steak at the end of 2018.It was co-founded only one year prior together with The Kitchen Hub from the Strauss Group, and with Professor Shulamit Levenberg of the Technion Institute of Technology. And in fall of 2019,Aleph Farmssuccessfully3D printedmeat on the International Space Station. Our experiment ofbioprintingmeat in space... consisted of printing a small-scale muscle tissue using 3D Bioprinting Solutions bioprinting technology, says Yoav Reisler, External Relations Manager for the company. The proof of concept sought to assess the potential of producing cultivated meat in a zero-gravity environment away from land and local water resources. Our approach for cultivating beef steaks is imperative to the experiment, as it relies on mirroring the natural process of tissue regeneration that happens in a cows body but under controlled and animal-free conditions. Our overarching goal is to produce meat products that have a significantly reduced ecological impact and this was a milestone in towards achieving that. Earlier this month, Aleph Farms announced plans to open an educational complex next to its production facility to provide the general public a more in-depth view of how cell-based meat is grown.

Thin-cut beef steaks cultivated by Aleph Farms.

Also in Israel,BioFood Systemsaims to produce beef products using bovine embryonic stem cells. It also hopes to scale up technology that it can license globally toenable meatmanufacturers to produce their own cell-based meat.

But other parts of the world arent far behind Israel, including Asia. Singaporean Shiok Meats is working on bringing cell-based based crustaceans (shrimp, crab and lobster) to market, and says its the first company of its kind in Singapore and South-East Asia. It hopes to have a commercially viable product in the next few years, and is currently researching and developing.

Shiok Meats cell-grown shrimp dumplings.

And in Japan, meat producer Toriyama and its export agent, Awano Food Group has partnered with JUST to grow, distribute and sell its cell-based wagyu beef worldwide.

JUST doesn't yet have images of its cell-based wagyu because its still in early stage R&D, but it ... [+] may one day look like this animal-based piece of Wagyu beef steak seen here.

In-between Asia and Europe, innovation is also happing in Turkey. Biftek is the first and still the only companydeveloping cultured meat in the country. It uses a plant-based formulation, made up of 44 proteins, in place of fetal bovine serum. Founder Can Akcali said in a recent interview that the media in Turkey is showing a growing interest in its work, and cell-based meat more widely.

Since the first cell-based unveiling of a cell-based burger in 2013, scientists have been flocking to labs in a race to iron out numerous teething problems and be the first to make a commercially viable cell-based meat product. Meanwhile, private investment into the industry has soared. Last year, twelve companiesraised $50 million in 14 deals double the amount of 2018. US-based Memphis Meats raised $22 million, Spain's Cubiq Foods raised $14 million and Mosa Meat drew in $9 million.

Memphis Meats now plans to build a pilot production facility,thanks to additional investments in January this yearfrom Cargill and Tyson Foods, as well as high-profile investors Bill Gates, Richard Branson, and Kimbal Musk.

Ido Savir, SuperMeats chief executive, said Mosa Meat introduced the concept of cell-based meat to the world, and that the main challenge start-ups are still facing is proof of scaling up production to a commercially viable size that's cost-efficient. Once these hurdles are overcome, it will be a much smoother process to get cell-based meat on shelves. At the moment, cell-based products are being prototyped in labs - but once scientists have finessed the process and the cost, theyre produced at scale and can grow in facilities like any other food.

Many cell-based start-ups expect to get their products to market in the next few years. Whether or not they are actually able to meet that projection is an open question. I worry most startups in the cultured meat space are overestimating their short-term timeline to get to market and underestimating their potential long-term impact on completely redesigning our food system from the cell-level up, says Max Elder, Research Director in the Food Futures Lab at Institute for the Future. Regardless of the timeline, one thing is clear: we desperately need to undo the damage industrialized animal agriculture is wreaking on our communities, animals, and the planet. While it may indeed be unwise to count our cultured chickens before they hatch, especially in light of the urgent challenges we are facing, we can no doubt expect more innovation in the coming years. Perhaps one day - even if not in the near future - all the meat on our plates will indeed be slaughter-free.

Visit link:
Will Cultured Meat Soon Be A Common Sight In Supermarkets Across The Globe? - Forbes

Read More...

The Benefits of Intermittent Fasting – The New York Times

Monday, February 17th, 2020

Although there have been a number of recent studies assessing the effects of intermittent fasting on people, none are long term, and the vast majority of disease-related findings stem from research on laboratory animals. For example, in an animal model of stroke, those fed only intermittently suffered less brain damage because they were better able to resist the stress of oxygen and energy deprivation.

Other animal studies have shown a robust disease-modifying benefit of intermittent fasting on a wide range of chronic disorders, including obesity, diabetes, cardiovascular disease, cancers and neurodegenerative brain diseases, the researchers reported. Their review of both animal and human studies found improvements in a variety of health indicators and a slowing or reversing of aging and disease processes.

For example, human studies of intermittent fasting found that it improved such disease indicators as insulin resistance, blood fat abnormalities, high blood pressure and inflammation, even independently of weight loss. In patients with multiple sclerosis, intermittent fasting reduced symptoms in just two months, a research team in Baltimore reported in 2018.

If you think evolutionarily, Dr. Mattson said, predators in the wild fight for prey in the fasting state and are better at recovering from inevitable injuries. The human counterpart people who evolved in feast-or-famine environments would not have survived unless somehow protected by fasting.

Our human ancestors did not consume three regularly spaced large meals, plus snacks, every day, nor did they live a sedentary life, the researchers wrote. The studies they analyzed showed that most if not all organ systems respond to intermittent fasting in ways that enable the organism to tolerate or overcome the challenge and then return to normal.

Dr. Mattson explained that during a fast, the body produces few new proteins, prompting cells to take protein from nonessential sources, break them down and use the amino acids to make new proteins that are essential for survival. Then, after eating, a lot of new proteins are produced in the brain and elsewhere.

A reasonable question might be How safe is intermittent fasting? When fats are used for energy, they produce substances called ketone bodies that regulate the expression and activity of many proteins and molecules that are known to influence health and aging, the researchers reported. Ketosis, a build-up of acidic ketones in the blood, is a state that the Atkins diet, the ketogenic diet and other carbohydrate-restricted diets aim to achieve. Taken to extremes, however, ketosis can damage the liver, kidneys and brain and is especially dangerous to people with various chronic disorders like diabetes and heart disease.

Follow this link:
The Benefits of Intermittent Fasting - The New York Times

Read More...

Validea’s Top Five Healthcare Stocks Based On Motley Fool – 2/16/2020 – Nasdaq

Monday, February 17th, 2020

The following are the top rated Healthcare stocks according to Validea's Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks with solid fundamentals and strong price performance.

CORCEPT THERAPEUTICS INCORPORATED (CORT) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 83% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

ZYNEX INC. (ZYXI) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 83% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: Zynex, Inc. operates through the Electrotherapy and Pain Management Products segment. The Company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc. (ZMI). Its other subsidiaries include Zynex Monitoring Solutions, Inc. (ZMS) and Zynex Europe, ApS (ZEU). ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. ZMS is in the process of developing its blood volume monitoring product for non-invasive cardiac monitoring. ZEU intends to focus on sales and marketing its products within the international marketplace, upon receipt of necessary regulatory approvals. It markets and sells Zynex-manufactured products and distributes private labeled products. Its products include NexWave, NeuroMove, InWave, Electrodes and Batteries. ZMI devices are intended for pain management to reduce reliance on drugs and medications.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

INMODE LTD (INMD) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 79% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: Inmode Ltd is an Israel-based company. It designs, develops, manufactures and commercializes energy-based, minimally-invasive surgical aesthetic and medical treatment solutions. The Company's proprietary technologies are used by physicians to remodel subdermal adipose, or fatty, tissue in a variety of procedures including fat reduction with simultaneous skin tightening, face and body contouring and ablative skin rejuvenation treatments. Its products target a wide array of procedures including simultaneous fat killing and skin tightening, permanent hair reduction, skin appearance and texture, among others. The Company's products may be used on a variety of body parts, including the face, neck, abdomen, upper arms, thighs and intimate feminine regions. It owns six product platforms: BodyTite, Optimas, Votiva, Contoura, Triton and EmbraceRF. All are market and sell traditionally to plastic and facial surgeons, aesthetic surgeons and dermatologists, among others.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

MEDPACE HOLDINGS INC (MEDP) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 76% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: Medpace Holdings, Inc. is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company's drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company's operations are principally based in North America, Europe, and Asia.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

CRISPR THERAPEUTICS AG (CRSP) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 72% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: CRISPR Therapeutics AG is a Switzerland-based gene-editing company. It focuses on the development of transformative gene-based medicines for serious diseases. The Company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The Company has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine and rare diseases. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The Company has business operations in London and the United Kingdom, as well as research and development operations in the United States.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

Since its inception, Validea's strategy based on Motley Fool has returned 625.78% vs. 240.03% for the S&P 500. For more details on this strategy, click here

About Motley Fool: Brothers David and Tom Gardner often wear funny hats in public appearances, but they're hardly fools -- at least not the kind whose advice you should readily dismiss. The Gardners are the founders of the popular Motley Fool web site, which offers frank and often irreverent commentary on investing, the stock market, and personal finance. The Gardners' "Fool" really is a multi-media endeavor, offering not only its web content but also several books written by the brothers, a weekly syndicated newspaper column, and subscription newsletter services.

About Validea: Validea is an investment research service that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More here:
Validea's Top Five Healthcare Stocks Based On Motley Fool - 2/16/2020 - Nasdaq

Read More...

My Third Stem Cell Treatment for MS – Everyday Health

Saturday, February 15th, 2020

Since 2014, I have had three stem cell treatments, each time hoping it would help fight off the progression of my multiple sclerosis (MS) symptoms. Because the procedures Ive undergone do not have a very long history of use or many studies to support them, Ive basically made myself a guinea pig by trying them.

So far, Ive experienced failure and success, but overall, the positives have been life-changing for me. I am continuing down this path of healing because there is currently no cure for MS, and now that Im 61, time is not on my side for a cure to be discovered!

In 2014, I had a procedure in which adult stem cells were isolated from my fat tissue, grown in a lab, and reinfused into my body. Initially I had great results, but they were short-lived, and within three months, all my MS symptoms had returned.

In 2018, I had a different type of procedure, in which 300 million stem cells derived from umbilical cord tissue were infused into my arm. I wrote about my experience in a blog just two months after that infusion. At the time, I was having a positive response, but I was also skeptical, since I had seen similar early improvements in 2014.

Two weeks after my 2018 treatment, my left-side drop foot was gone, I could jump off the floor, and I had regained some feeling in my left arm. But I needed to give this new stem cell treatment some more time before I could positively state that this one had worked. So I waited and kept working out in the gym as I have always done, pushing myself harder as time went by.

I found my body getting stronger and stronger as the months passed, and I even filmed myself squatting 500 pounds and posted it in our MS Fitness Challenge GYM Facebook group to show the community that I was not just imagining the results.

Months after the treatment, my left leg was almost as good as my right one, which has never been affected by MS, and my overall strength was increasing.

By the eighth month or so, I was running on the treadmill, and at approximately nine months post-infusion, I was jumping rope. I had not run or jumped rope in almost 14 years.

I was and am extremely happy with what my legs are now capable of, but I only got partial feeling back in my left arm and hand, and I want that back the same way I have my left leg back.

With that goal in mind, I reached out to the doctor who had performed my stem cell procedures and asked if I was eligible for more cells. I also asked if he thought more cells would bring back the feeling in my left arm and hand.

His response was that no one had predicted what results I would get from the 2018 treatment, and here I was running, jumping rope, and squatting like a champion. So we had nothing to lose by transfusing another 300 million cells into my body. We both thought that since my leg no longer needed the stem cells, maybe they would find their way to my arm!

Theoretically, stem cells go where theyre needed to repair the damage.It seemed worth a shot, so I booked my flight to the Cayman Islands for a January 2020 infusion. And now I am home.

Its only been a few weeks, but I can already feel hot and cold in my left hand, which I have not been able to do since 2006, when I was diagnosed.

Again, I am cautiously optimistic that I will get similar results in the areas I need them now. But only time will tell. All I can say is that this therapy has changed my life, and I am hopeful that an ongoing clinical trial of the stem cell treatment I received will provide evidence that it will also be helpful to others with MS.

See the rest here:
My Third Stem Cell Treatment for MS - Everyday Health

Read More...

Indian doctors fix Yemeni man’s face in rare reconstructive surgery – The New Indian Express

Saturday, February 15th, 2020

By Express News Service

NEW DELHI: A 26-year-old man from Yemen received a fresh lease of life through a rare reconstructive surgery, performed by a team of Indian doctors. A few months back, the patients face and mouth was left completely disfigured after a mobile phone exploded while he held it between his teeth. Apart from severe disfigurment, the accident rendered him incapable to eat and speak properly.

The patient was admitted at KAS Medical Centre in the national capital where a team of facial reconstruction surgeons headed by Dr. Ajaya Kashyap performed a rare surgical procedure to give him his normal facial features back. As per the doctors, the blast was so strong that it burnt the inside of his mouth, tore up the muscles and the tongue leaving all the soft tissues damaged.

As the blast happened inside the mouth, the injury was rather unusual. After much assessment, the team decided to use flaps of tissue from inside the mouth as well as fat tissues from his body and use it as a flap. Ensuring facial sensations was another challenge. We are happy that the procedure went well and the patient regained his normal features, said Kashyap, Medical Director, KAS Medical Centre.

The muscles of the lips which had been split apart were repaired and flaps were used to close it. Autologous fat with stem cells and PRP were injected to restore volume and improve scarring.

The surgery was done a week back and now he is ready to fly back to his own country, added Kashyap.

Mobile phone blasts have lead to serious injuries in India. The most common reasons for a cell phone to explode are using it while the phone is being charged. Charging puts pressure on the device, using it during charging increases this pressure manifold. This causes cheap electronic components in some mobiles to explode.

Originally posted here:
Indian doctors fix Yemeni man's face in rare reconstructive surgery - The New Indian Express

Read More...

Page 6«..5678..20..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick